Clinical trial failures
Could delay or halt drug development
- Materiality
- high
IRLAB Therapeutics
IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders. Originating from Nobel Prize-winning research, the company leverages its proprietary Integrative Screening Process (ISP) to create first-in-class drug candidates. IRLAB's pipeline includes several promising compounds targeting different stages and symptoms of Parkinson's, with the potential to significantly improve patient outcomes. The company is listed on the Nasdaq Stockholm and is recognized for its strategic focus on CNS disorders.
31
0.80
0.80
| % | |
|---|---|
| Parkinson's Disease Treatments | 70% Includes drugs targeting various stages and symptoms of Parkinson's. |
| CNS Disorder Treatments | 20% Drugs for other central nervous system disorders beyond Parkinson's. |
| Research Platform Licensing | 10% Licensing of the proprietary ISP research platform. |
IRLAB Therapeutics primarily serves the pharmaceutical and healthcare sectors, focusing on partnerships with large...
- Pharmaceutical Companiesprimary
They buy drug candidates for CNS disorders to expand their treatment portfolios.
- Research Institutionssecondary
They collaborate on clinical trials and research for Parkinson's treatments.
- Licensing Partnersemerging
They license the ISP platform for drug discovery and development.
IRLAB Therapeutics is headquartered in Gothenburg, Sweden, and operates primarily within the European market...
- •Headquartered in Gothenburg, Sweden
- •Listed on Nasdaq Stockholm, enhancing Nordic presence
- •Collaborates with US and European regulatory bodies
- •Focus on European market for clinical trials and partnerships
- •Leverages regional expertise in CNS disorder treatments
IRLAB's strategic priorities include advancing its drug candidates through clinical trials, particularly focusing on...
01
Advance clinical trials for mesdopetammedium-term
To treat levodopa-induced dyskinesias effectively
02
Expand patent portfolioshort-term
To protect innovations and extend exclusivity
03
Secure strategic partnershipsmedium-term
To fund and support R&D efforts
IRLAB faces several risks, including the inherent uncertainties of drug development, such as clinical trial failures...
Regulatory hurdles
Impact approval and commercialization
- Materiality
- high
Financial dependency
Relies on external funding for R&D
- Materiality
- medium
Revenue recognition
Financial instruments valuation
Milestone payments timing
BioArctic
BIOA-B.ST · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
CRISPR Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
RELMADA THERAPEUTICS, INC.
RLMD · Pharmaceutical Preparations
Hansa Biopharma
HNSA.ST · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
: 11/08/2026